Report #13
Poly-MVA
PALLADIUM LIPOIC COMPLEX
The anti-cancer nutrition


There is a lot of publicity surrounding a new cancer treatment protocol that is presently undergoing clinical trials in the USA, but has been used for years by hundreds of physicians around the globe. It is called Poly-MVA.

This is how it is described at http://polymvasurvivors.com/about_poly.html:

Poly-MVA is a new, nontoxic, powerful antioxidant formula that protects both cellular DNA and RNA. The scientifically designed mechanism of action is to “fix the cell” and control the cancer, rather than “fight the cancer” and poison the system. This method of cancer treatment has clearly demonstrated safe, antitumoral activity. Compared to chemotherapy, Poly-MVA offers an extremely powerful alternative cancer treatment without the toxic side effects associated with most Conventional Cancer Treatments.

Poly-MVA is proving to be a viable alternative cancer treatment due to its patented antiaging formula. Many of the signs we contribute to aging can be slowed through the Poly-MVA cell protection. Doctors and Patients worldwide are reporting the benefits of Poly-MVA.


Merrill Garnett, a doctor and research chemist, of the Garnett McKeen Laboratory, in Stony Brook, New York is the inventor and recipient of three U.S. patents for Poly-MVA. Dr. Garnett discovered the world’s first nontoxic “chemotherapy” agent which does no harm to the healthy cells. Poly-MVA, however, is not so much a ‘drug’ as a ‘cell nutrient’ or superfood supplement.

For nearly forty years, Dr. Garnett has probed the secrets of molecular biology and the mysteries of cells, following his revolutionary dream for a safe and effective treatment for cancer. He saw cancer as the failure of cells to regenerate normally in a default mode; instead cloning itself within the cancer mechanism over and over again. He decided this failure to mature was a problem of energetics in the cell's metabolic processes.

Dr. Garnett began the often lonely search to find a molecular compound that would restore healthy pathways for growth and normal development within the cell—pathways missing in the cancer cells. He searched for a metallo-organic compound that would act as a molecular shunt to restore the cell’s healthy energetics.


In 1991 and some 20,000 compounds later
, he discovered that palladium combined with lipoic acid, B-12 and thiamine created an extremely useful and safe cellular nutrient. Subsequent tests have proved that Poly-MVA is a safe and effective antitumoral agent.


In 1995 Dr. Garnett patented a non-toxic chemotherapeutic agent targeting only the malignant cells which agent, at the same time, is related to specific changes in energy metabolism. This compound was named POLYDOX (U.S. trials) or Poly-MVA (Canada and Mexico), or LAPd by some researchers. The MVA stands for minerals, vitamins, and amino acids, and LAPd is Lipoic Acid/palladium complex. When lipoic acid, a powerful antioxidant with many biological functions, is connected to an electrically charged metallic substrate, and joined with various B vitamins, the resulting complex becomes totally soluble in water and fat. It can easily and safely travel throughout the body and into every cell, crossing the blood/brain barrier as well. Therefore, performing that journey across the blood/brain barrier - impossible for most drugs, including chemotherapy - makes Poly-MVA excellent in cases where no other remedies are possible. Poly-MVA has shown to be beneficial in cases of breast, prostate, colon, lung, stomach and brain cancer, and has also been used successfully in cases of psoriasis - a disease which often develops into cancer.



Writes Dr. Stephen Sinatra M.D., F.A.C.C.:

"You haven't seen Poly-MVA on the six o'clock news or Sixty Minutes yet, because patient trials are still being conducted in this country. But I'm already recommending Poly-MVA to every new cancer patient. Why am I so confident about Poly-MVA? First, this natural remedy is already being used in Europe, Australia, South America and India. Plus, Poly-MVA is a natural substance (a combination of Alpha Lipoic Acid and the element Palladium) and has absolutely no side effects, unlike radiation, chemotherapy or surgical removal.

Simply said, Poly-MVA seeks out and destroys any cancer cells in your body by stealing their electromagnetic energy. In other words, it pulls the cancer cells' batteries out, and the dead cancer cells are flushed out of your body. At the same time, Poly-MVA invigorates your normal cells, helping repair any damage the cancer may have done."


http://altmedangel.com/polymva.htm , a non-profit organization, reports on the following early clinical cases:

Clinical Studies

The first report of clinical studies of PolyMVA was presented by the late Rudolf E. Falk, an oncological surgeon at the University of Toronto, in March 1994. Dr. Falk reported that the compound was administered intravenously, subcutaneously (under the skin) and per Os in a modified phase 2 study. To quote from Dr. Falk's summary, "95 patients were treated; these included breast, lung, colorectal, prostate, pancreatic, ovarian, malignant melanoma and primary brain neoplasia. 90% of the patients were in the category of having failed all available therapy. 88 are surviving on therapy with a mean survival time of 9 months. The anticipated survival time of this group, from available statistics would vary from 20% to 60% at 6 months. All of these patients received moderate doses of chemotherapy."

The first 27 patients given PolyMVA were all considered terminal, and all refused to continue with chemotherapy. They were placed on a "health promotion program" as outlined in The Definitive Guide to Cancer, Chapter 23. The cancers involved brain, tongue, esophagus, lung, breast, stomach, colon, pancreas, prostate, lymph, blood, and marrow. All had metastasis. All were given 5 drops four times daily as a loading dose. 13 reported improvements in either appetite, weight gain, increased energy or reduction in pain within the first 7 days of starting PolyMVA. At the end of 14 days 6 additional patients reported improvement. None of the 27 patients reported adverse reactions.

We learned from this small study (1) that the initiating dose was inadequate, (2) rapid improvements can be expected in over 60% of patients with a variety of malignant conditions, and (3) PolyMVA is non-toxic. With this low dose, some patients demonstrated clinical changes indicating early improvement. A few anecdotal reports follow:

75 year old female with glioblastoma presented with history of debulking surgeries and 2 rounds of radiation. As a last resort her cancer center neurologist placed her on massive, experimental doses of tomoxifen. She entered the hospital in Baja California requiring support on both arms to walk up the short ramp. Her memory was impaired, she had slurred speech. Convulsions were under control with dilantin. On the 3rd day after beginning PolyMVA her memory had improved as had her slurred speech. She walked out of the hospital unaided to continue therapy at home. She lived 6 months. Her immediate death is attributable to the side effects of the tamoxifen which she continued to take before and after the PolyMVA.

Glioblastoma patients usually have a dramatic, early response similar to Mr. D. age 66. His tumor inactivated his right leg and foot and caused generalized convulsions which were poorly controlled by tegretol, or dilantin. I received a phone call from Mr. D. four days after he began PolyMVA. He said his paralysis was gone and he could walk outside and water the lawn and ride his stationary bicycle. Eight days after beginning he called again to report that his convulsions were now localized and almost gone.

Pain from metastatic breast cancer to the spine and right hip in CF age 56 required a right hip replacement which gave relief from hip pain, but did not effect the spine. She started PolyMVA and within 2 weeks her "back pain stopped" and she returned to her legal research employment. Most breast cancer patients report at least temporary improvement.

Two cases of cancer of esophagus requiring MS for pain relief, cachectic and terminal when they started PolyMVA. Mr. G. age 62 was in a Mexican hospital when he was scheduled to began the PolyMVA. LS age 45 took the PolyMVA for home use. Mr. G died within 6 weeks, but an investigation uncovered the fact hat he was never given the PolyMVA. He was given Laetril alone. LS reported increased strength and weight gain and is still living (2 years from starting PolyMVA).

Diagnosed in April 1995 a female multiple myeloma patient from Alaska with two degrees, a Ph.D. and J.D. sent us a letter dated March 1997 that after taking PolyMVA her blood tests and examinations showed " no measurable signs of multiple myeloma carcinoma" and her doctors said "She is in total remission."

Colon cancer patients with obstruction reported improvement using the PolyMVA by enema. This is logical since PolyMVA is soluable in fat and liquid.



Clinical studies by Dr. Forsyth

Dr. James Forsythe has been conducting a Poly-MVA outcome based investigation on various Stage IV Cancers since January of 2004 in Reno, Nevada and has seen encouraging results. "We have seen patients go into full remission with aggressive, stage IV cancers and we see continued positive responses in others with previously chemo-resistant cancer. Other benefits from Poly-MVA are a significantly improved quality of life and a substantial reduction in the number and severity of side effects from chemo and radiation therapies."

To date, 207 patients are involved in the investigation. The patients are classified into two groups. The first group is administered both the Poly-MVA and chemotherapy. The other group, who refused chemotherapy were on the supplement only. In both groups, the Poly-MVA dosage is administered intravenously for a fifteen day period. The patient is then switched to an oral dosage which could take it up to six to eight months. After six months a maintenance dosage is administered depending upon the remission of the tumor. Because this is an ongoing clinical study, there is no charge for the supplement, but there is a small administrative fee.

The Poly-MVA clinical results: a 70 percent response rate which included partial remission and complete remission responses in the group that received both the chemotherapy and Poly-MVA supplement and a 42 percent response rate from the group who received the supplement exclusively. (Partial reduction means a 50 percent reduction in the size of the tumor mass and complete reduction means a disappearance of the disease resulting from a physical examination, scanning and tumor markers.)


For further information on animal and human studies, go to
Poly-MVA: Research and Clinical Experience in Individuals with Strokes, Cancer and Anti-Aging Concerns
Mitchell Fleisher, M.D., D.Ht., D.A.B.F.M.

Poly-MVA and prostate health: Shari Lieberman PhD, CNS, FACN discusses cancer case studies with the Foundation for Advancement in Cancer Research (Sept.2006)

FACR: What can be done nutritionally to support conventional prostate cancer treatments?

Dr. Lieberman: Poly-MVA is an excellent choice both for those who choose the "watchful waiting" approach and those that want nutritional support as an adjuvant to standard treatment.

FACR: Poly-MVA is said to have a particularly interesting mechanism of action. Can you describe this?

Dr. Lieberman: It actually has a two-step process for its mechanisms of action. Poly-MVA is comprised of an irreversibly bound trimer of lipoic acid, a powerful water and fat-soluble antioxidant, and the mineral palladium with a thiamine (B1) core. Consequently, it exists as a polymer rather than as a single molecule. That means Poly-MVA can accept and donate energy (electron charge) at a much greater magnitude then a single molecule like other nutrients. This enables Poly-MVA to shuttle energy to the mitochondria while, at the same time, protecting DNA and other cellular tissue from oxidative stress or free radical damage that occurs during normal cellular metabolism and, especially, during times of disease (like cancer) or during the course of treatments (like radiation and chemotherapy). Essentially, Poly-MVA converts free radicals into usable cellular energy, benefiting and nourishing normal cells.

FACR: Does this mean that Poly-MVA can provide the same energy to cancer cells?

Dr. Lieberman: No. Studies and much research have demonstrated that cancer cells are unable to accept the excess energy Poly-MVA provides. This is because malignant cells function in a hypoxic (low oxygen) environment, typically using sugar to generate the energy needed to survive. The production of oxygen radicals from the energy transfer generated in a hypoxic environment facilitates cancer cell death by activating enzymes that destroy the cells. Unlike cancer cells, healthy cells are richly oxygenated. Consequently, Poly-MVA is non-toxic to the healthy cells, which benefit from the energy boost and protective effect triggered by the Lipoic Acid Palladium complex.

From the website of Dr. Forsythe (http://www.drforsythe.com/cw/poly.php):

Poly-MVA Stage IV Cancer Investigation
James W. Forsythe M.D., H.M.D.

“We have seen patients go into full remission with aggressive, stage IV cancers and we see continued positive responses in others with previously chemo-resistant cancer. Other benefits from Poly-MVA are a significantly improved quality of life and a substantial reduction in the number and severity of side effects from chemo and radiation therapies.” --Dr. James Forsythe

Dr. James W. Forsythe M.D., H.M.D. has been conducting an outcome based Investigation on various Stage IV Cancers since January of 2004 in Reno, Nevada.

To date, 207 patients have enlisted in the Investigation and thus far a 56 percent overall positive response rate has been noted. Most patients are using a full dosing (eight teaspoons per day) schedule. For updated results on the Investigation, please click on the following link Poly-MVA Investigation presentation.

For Dr. Forsythe, Poly-MVA has now set a protocol for his combined approach because in his experience using Poly-MVA with advanced cancer patients has been extremely promising.

From patients:

Marilyn Haro-Smith who is suffering from inoperable lung cancer and was told she had only three to six months to live, has seen encouraging results from the Poly-MVA."During the past five years I have been treated by Dr. Forsythe with both low-dose fractionated chemotherapy and alternative therapies.  One year ago my cancer markers were going up and Dr. Forsythe placed me on his clinical out-come based protocol with Poly-MVA.  Since then, this natural supplement has stabilized my disease and normalized my markers." 

Michael Oliver who has been battling prostate cancer tells his story. "My PSA began to rise one year ago and Dr. Forsythe placed me on his clinical investigation with oral Poly-MVA and since this time my PSA has been near normal and I have not required any chemotherapy.  I have had no side-affects from the Poly-MVA.  I feel better and have more energy." 

Currently, the Dr. Forsythe’s Poly-MVA clinical investigation is completed.  Dr. James Forsythe's investigation was the largest and included treating all types of cancer. Dr Forsythe is as an Associate Professor of Alternative Medicine at the University of Nevada, Reno. 

To see if Poly-MVA is right for you or your loved one, please give us a call. For more information or questions on Poly-MVA, please call our office during regular business hours at 775-827-0707

The top three cancers that were highly responsive to the Poly-MVA treatment were prostate, breast and non-small cell lung cancer.  Surprisingly non-small cell lunge cancer is, in general, not a high responder to conventional treatments. Colorectal cancers were the least responsive.

Poly-MVA appears to be a safe and effective natural food supplement for palliative assistance in Stage IV cancer patients either with or without concomitant chemotherapy.

The safety profile is excellent and there was no treatment-related deaths or any significant adverse reactions or negative interactions with chemotherapy or hormonal treatments.

An IV loading dose of Poly-MVA confers a 12 percent improved overall response rate in this investigation.

Dr. James Forsythe's "Poly-MVA Outcome Based" investigation included treating all types of cancer. Dr Forsythe is as an Associate Professor of Alternative Medicine at the University of Nevada, Reno. 

This investigation has been presented to the Nevada State Board of Homeopathic Medicine. This investigation has not received FDA approval; however, an IRB is pending in the State of Nevada.



From the Townsend Letter for Doctors & Patients: a long and extremely informative article about Poly MVA, including clinical cases, written by Dr. Morton Walker: http://www.townsendletter.com/FebMar_2003/polymva0203.htm


How does Poly-MVA work?
For an illustrated explanation,
click here.
For a list of practitioners, click here. (Please note: Some of the addresses in these lists may not be valid.)

Posted on Foundation for Advancement in CANCER RESEARCH

Post Date : Friday July 21 2006

New York City "A new proprietary product called Poly-MVA has shown highly promising preliminary results in stabilizing prostate cancer without producing any of the dreaded side effects commonly associated with conventional treatments, according to a just-published report.

Authors of the report, Dr. Shari Lieberman, Ph.D., C.N.S., F.A.C.N. and Dr. James W. Forsythe, Certified Board Oncologist, M.D., H.M.D., thoroughly documented the case studies of three men "ages 59, 73 and 77" who were diagnosed at various stages of prostate cancer and adamantly refused any conventional treatment.

"The reason these men refused conventional treatment is because they were so worried about the potential side effects, including impotence, incontinence and loss of sexual desire" Dr. Lieberman says. "They just said no".

The patients were given Poly-MVA while being closely monitored by an oncologist. All three showed dramatic improvement, with significantly lowered PSA levels and scores of 100 percent on a performance scale. They also experienced significant improvement with such associated symptoms as nocturia (excessive urination at night) dysuria (painful or difficult urination), and hematuria (blood in the urine). Two of the men remain sexually active; the third was inactive before treatment started.

"The patients are happy and very satisfied with the outcome," Dr. Lieberman says. "They feel great and continue to take Poly-MVA while being monitored by their oncologist."

Used as a dietary supplement, Poly-MVA (which stands for POLY-Palladium Lipoic Complex and MVA- minerals, vitamins and amino acids) contains a proprietary formulation of palladium, alpha-lipoic acid, molybdenum, rhodium, ruthenium, thiamine, riboflavin, cyanocobalamin, formyl-methionine, and N-acetylcysteine. The primary active ingredient, a lipoic acid/palladium complex, or "LAPd" for short, has undergone extensive testing and is considered extremely safe with 15 years of human use.

Preliminary research on LAP suggests that it may also improve outcomes in a patient receiving radiation and chemotherapy by helping to protect normal, healthy cells while the patient is receiving treatments. Additionally, Poly-MVA may provide healthy cells with a boost in energy, which could explain why all three men scored so high on the performance scale.

With a new case of prostate cancer diagnosed every 2.6 minutes, the authors say the obvious benefit of these three case studies is that other patients who refuse conventional treatment may also benefit by taking Poly-MVA while being closely monitored by an oncologist.

"While these cases are moderate in duration (7-12 months) they provide compelling evidence that this formulation may be worthwhile for men who refuse any conventional treatment," the authors wrote.

The complete study is published in Alternative & Complementary Therapies, August 2005 and is available at the publisher's website at www.liebertonline.com.

Shari Lieberman, Ph.D, C.N.S., F.A.C.N., is a research scientist and industry consultant based in New York City and Pompano Beach, Florida. She is also the Founding Dean of New York Chiropractic College’s (Seneca Falls, NY) MS Degree Program in Clinical Nutrition.

James W. Forsyth, M.D., H.M.D., is the medical director of the Century Wellness Clinic, Reno, Nevada, and an associate professor of medicine and pathology at the University of Nevada Medical School, also in Reno.


Abstracts on clinical trials


 
 1.  
Poly-MVA for Treating Non–Small-Cell Lung Cancer: A Case Study of an Integrative Approach
Shari Lieberman, James W. Forsythe
Alternative & Complementary Therapies. Apr 2006, Vol. 12, No. 2: 77-80
Abstract


 
 2.  
Poly-MVA for Treating Prostate Cancer: A Report on Three Cases
Shari Lieberman, James W. Forsythe
Alternative & Complementary Therapies. Aug 2005, Vol. 11, No. 4: 203-207
Citation


 
 3.  
Quality Assessment of Affymetrix GeneChip Data
Steffen Heber, Beate Sick
OMICS: A Journal of Integrative Biology. Sep 2006, Vol. 10, No. 3: 358-368
Abstract


 
 4.  
IL-12/GM-CSF Coadministration in an SIV DNA Prime/Protein Boost Protocol Enhances Gag-Specific T Cells But Not Virus-Specific Neutralizing Antibodies in Rhesus Macaques
Eduardo O'Neill, Vanda Bostik, David C. Montefiori, Edmundo Kraiselburd, François Villinger
AIDS Research and Human Retroviruses. Oct 2003, Vol. 19, No. 10: 883-890
Abstract


 
 5.  
Development of a Safe and Rapid Neutralization Assay Using Murine Leukemia Virus Pseudotyped with HIV Type 1 Envelope Glycoprotein Lacking the Cytoplasmic Domain
Young B. Kim, Myung K. Lee, Dong P. Han, Michael W. Cho
AIDS Research and Human Retroviruses. Dec 2001, Vol. 17, No. 18: 1715-1724
Abstract


 
 6.  
Phase I Study of Dystrophin Plasmid-Based Gene Therapy in Duchenne/Becker Muscular Dystrophy
Human Gene Therapy. Nov 2004, Vol. 15, No. 11: 1065-1076
Abstract


 
 7.  
Mucosal AIDS Vaccines
Aldar S. Bourinbaiar, Orapun Metadilogkul, Vichai Jirathitikal
Viral Immunology. Dec 2003, Vol. 16, No. 4: 427-445
Abstract

Francis J. Antonawich, Ph.D. , research involving Poly-MVA click here.


From http://www.drlam.com/private/poly_mva.cfm ,

Updated Guidelines for the Use of Poly-MVA

Poly-MVA is safe, even for pregnant women, nursing mothers, and children under the age of two. Extensive testing, both in the laboratory and in the field over the last ten years, has proven this. There is no known level of Poly-MVA above which toxicity will occur. Poly-MVA does not harm normal cells -- even rapidly-dividing ones. Poly-MVA hydrates and energizes normal cells, while either normalizing or killing abnormal cells.


Books about Poly-MVA on Amazon:
http://www.amazon.com/Poly-MVA-Supplement-Fight-Against-Cancer/dp/1591200490
http://www.amazon.com/First-Pulse-Personal-Journey-Research/dp/0966559703


Sources (where to order):

http://www.e-spa.net/Supplements-Poly_MVA.html
http://www.antiaging-systems.com/a2z/poly-mva.htm
http://www.polymva.net/
http://www.biohealthonline.com/?gclid=CJ2n8cOogYsCFSWHPgod3G1dKg
http://www.polymva.org/
http://www.polymva.org/faqs.htm#a
http://www.poly-mva.com/
http://www.ghchealth.com/poly-mva.php
http://www.polymva.biz/
http://healthequip-store.stores.yahoo.net/polymva8oz.html
http://www.naturodoc.com/mm5/merchant.mvc?Screen=PROD&Store_Code=NATURODOC&Product_Code=PMV-8&Category_Code=Cancer
http://www.worldwidehealthcenter.net/category.php?prod=879/

At Google, under the search term, poly-mva, you will find many more links.


What does Poly-MVA mean for the cancer patient?

It is a liquid supplement, taken orally.

The good news is, it is backed by good research data. Reputable physicians are using it with good result. It is not a drug, but a dietary supplement, so it is safe, non-toxic, no side effects. It can be taken orally, although the doctors who use it prefer to start intravenously, and only later do they switch to oral intake. According to posted literature, it is safe even for children under 2 years, for pregnant women and for nursing mothers; however, check this out with a licenced health care practitioner.

The fact that it crosses the blood/brain barrier gives hope to brain tumor patients. It is also recommended for leukemia. This is, without doubt, an important new tool in the hands of integrative doctors.

The other side of the coin is that it is expensive. It is not a magic bullet, not a panacea, yet for many, if not most cancer patients, Poly-MVA would consume most of their budget. If it works, that's great, but if it doesn't, there is no money left to switch to other treatments.

With cancer, monotherapies almost never succeed. A whole combination of remedies are needed, and some of the components in the combination may have to be changed to something else. The patient cannot afford to gamble on one drug or supplement, no matter how enthusiastically it is promoted.

I am not saying that the promotion is misleading. However, if you carefully examine it, it tells you that the treatment is far from perfect. It is a powerful product, but other products are also needed to ensure the desired outcome. So, what am I really saying?

In my opinion, it is a matter of budgeting. If the price of Poly-MVA doesn't exhaust most of your funds, Poly may be an excellent choice. However, if it eats up most of your funds, think carefully. There are other, much cheaper treatments available, and some of them may even be better than Poly-MVA.

Keep your options open.

© Gabe Bartha 2007. All rights reserved


HOME